The national myelodysplastic syndromes (MDS) natural history study, central lab and biorepository (CLB), task order 03, september 1, 2016-february 28, 2018

Ended Awarded Last action

Contract number
HHSN26800003
Awardee
Awarding agency
Obligated
$12,953,436

Award facts

Opportunity
Contract value 100% obligated
$12,953,435.66 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition Negotiated Proposal / Quote
Pricing
Cost No Fee
Place of performance
Tampa, FL 33612, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00010 $0
Supplemental Agreement for work within scope P00009 $0
Supplemental Agreement for work within scope P00008 $0
Other Administrative Action P00007 $0
Change Order P00006 $1,186,324
Change Order P00005 $0
Supplemental Agreement for work within scope P00004 $2,220,981
Supplemental Agreement for work within scope P00003 $4,438,388
Supplemental Agreement for work within scope 2 $2,973,923
Supplemental Agreement for work within scope 1 $0
Original award $2,133,819
Show all 11

About this award

The National Heart Lung and Blood Institute (NHLBI) awarded a delivery order contract to H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. to support the National Myelodysplastic Syndromes (MDS) Natural History Study as the Central Lab and Biorepository (CLB) provider. This Task Order 03, effective September 1, 2016 through February 28, 2018, carries a ceiling value of approximately $13.0 million and operates under a cost, no fee pricing structure. The award, issued on August 30, 2016, designates no set-aside provisions and specifies Tampa, Florida as the place of performance. As a non-profit, National Cancer Institute-designated comprehensive cancer center, Moffitt brings substantial expertise in biorepository management, laboratory operations, and research infrastructure to support the study's objectives.

The MDS Natural History Study represents a significant research initiative aimed at advancing understanding of myelodysplastic syndromes through systematic data and sample collection. By leveraging Moffitt's capabilities as a central laboratory and biorepository facility, the NHLBI can establish a standardized platform for specimen processing, storage, and distribution to support multi-institutional research. The ultimate completion date of February 28, 2026 indicates the broader program timeline extends well beyond the initial task order period, suggesting ongoing operational requirements and potential for additional renewal orders to sustain this critical research infrastructure supporting hematologic malignancy research.

Quick answers

Who was awarded contract HHSN26800003?

HHSN26800003 was awarded to H. Lee Moffitt Cancer Center And Research Institute Hospital, Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on August 30, 2016.

How much is contract HHSN26800003 worth?

The government has obligated $12,953,436 on HHSN26800003.

Is contract HHSN26800003 an order under another contract?

Yes. HHSN26800003 is a delivery order under HHSN268201400003I, an indefinite delivery contract.

Was contract HHSN26800003 competed?

The extent of competition for HHSN26800003 was full and open competition.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award